N/A N=36 chronOS Inject in Proximal Tibial Fractures
Closed Proximal Tibial Fracture Schatzker I - VI · Closed Proximal Tibial Fracture AO-OTA 41 · Closed Proximal Tibial Fracture AO-OTA 42
Primary: Fracture Union — 27; 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma
Malignant Melanoma
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) — 15 percentage of participants
Phase 4 N=395 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
Bladder Outlet Obstruction
Primary: The Global Response Assessment (GRA) After the Treatment Day — 89; 218; 27; 61 participants
Phase 1 N=45 Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients
Alzheimer Disease · Amyloid Beta-Protein
Primary: Quantitative Assessment of Neocortical SUVRs (Mean Standard Uptake Value Ratios) as a Measure of Florbetaben Uptake — 1.430; 1.726; 1.442; 1.738 SUVR — p=0.0001
Phase 4 N=44 Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes
Primary: Percentage of Participants With a Hematologic Response Using International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by Investigator…
Phase 2 N=142 Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasms
Primary: Number of Participants With Response — 0; 0; 3; 1 participants
Early Phase 1 N=55 Pilot Study on Mindfulness for Tobacco and Alcohol in University Students
Nicotine Dependence · Alcohol Use
Primary: Smoking Abstinence — 6; 1 participants
Phase 1 N=54 Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions
Acute Coronary Syndrome · Angioplasty, Transluminal, Percutaneous Coronary · Hydroxymethylglutaryl-CoA Reductase Inhibitors
Primary: Platelet - Leukocyte Aggregates — 29.2; 39.8; 26.2; 21.1 % leukocytes with platelets attached
Phase 2 N=74 A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Complete Histologic Clearance — 42.0; 16.0; 44.0 Percentage of participants — p=0.8463
Phase 1 N=11 Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
Cerebral Palsy (CP)
Primary: Safety and Tolerability of Dalfampridine-ER 10mg in Subjects With Cerebral Palsy (CP) — 1; 2; 6; 9 participants
Phase 3 N=580 A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) — 1.040; 1.191; 1.256 Liters — p=<0.001
Phase 2 N=43 Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
High Grade Gliomas · Brain Tumors
Primary: Median Progression Free Survival. — 10.5 months
Phase 3 N=460 Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy
Infantile Hemangioma
Primary: Interim Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at Week 24 Compared to Baseline Based on the Intra-patient Blinded Centralized…
N/A N=1,445 Development and Evaluation of an HIV, STD, and Pregnancy Prevention Program for Middle School Students
HIV Infections · Sexually Transmitted Diseases · Pregnancy
Primary: Initiation of Sexual Intercourse — 308; 509 participants
Phase 2 N=38 Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
Cervical Squamous Cell Carcinoma · Recurrent Cervical Carcinoma
Primary: Progression-free Survival Greater Than 6 Months — 30; 5 participants